Biotech Values

[DewDiligence]

AGTC IPOs 4.8M* shares @$12:

http://www.nasdaq.com/article/biotech-applied-genetic-technologies-prices-ipo-at-12-below-the-range-cm339167

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. AGTC's lead product candidates, which are each in the preclinical stage, focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are rare diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments.

I can’t find evidence that AGTC has actually begun trading.

*Assuming exercise of underwriter’s option.